Analysis finds biologics improve quality of life in psoriasis, while phototherapy remains cost-effective, indicating a need for coverage alignment.
In this study, biologics provided the largest quality-of-life gains, while step-therapy strategies achieved similar benefits with less variability and lower system costs. Phototherapy remained cost-effective for payers. Divergent incentives-payers favoring phototherapy and patients favoring biologics-underscore the need to align coverage, including reduced cost sharing for home phototherapy, to improve access and system sustainability.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: